Ignite Creation Date:
2024-05-06 @ 7:49 PM
Last Modification Date:
2024-10-26 @ 3:14 PM
Study NCT ID:
NCT06143540
Status:
RECRUITING
Last Update Posted:
2023-11-24
First Post:
2023-11-16
Brief Title:
Clinical Study of 18F-FAPI-RGD in Interstitial Lung Disease Associated With Connective Tissue Disease
Sponsor:
Sichuan Provincial Peoples Hospital
Organization:
Sichuan Provincial Peoples Hospital
Study Overview
Official Title:
Clinical Study of 18F Labeled Probe Targeting Fibroblast Activating Protein and Integrin avβ3 FAPI-RGD in Interstitial Lung Disease Associated With Connective Tissue Disease
Status:
RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this observational study is to examine clinical utility of 18F-FAPI-RGD PETCT imaging in evaluating connective tissue disease-associated interstitial lung disease Participants will undergo clinical evaluation and 18F-FAPI-RGD PETCT examination
Detailed Description:
Interstitial lung disease is an overarching term for a wide range of disorders characterized by inflammation and or fibrosis in the lungs Interstitial lung disease associated connective tissue diseasesCTD-ILD is one of the most common typesThe goal of this study is to explore the feasibility of using 18F-FAPI-RGD a dual-targeting heterodimeric PET tracer that recognizes both fibroblast activation protein FAP and integrin αvβ3 for detecting connective tissue disease associated interstitial lung disease CTD-ILD and analyze the relationship between 18F- FAPI-RGD PETCT images and related parameters of lung function clinical laboratory indicators and HRCT scores
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None